Geron Corporation (NASDAQ:GERN) Receives Average Recommendation of “Hold” from Analysts

Shares of Geron Corporation (NASDAQ:GERN) have been given a consensus recommendation of “Hold” by the ten brokerages that are presently covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $2.75.

Several equities research analysts recently weighed in on the stock. Needham & Company LLC cut their target price on shares of Geron from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. HC Wainwright reaffirmed a “neutral” rating on shares of Geron in a research report on Tuesday, December 9th. TD Cowen reiterated a “buy” rating on shares of Geron in a report on Thursday, January 29th. Weiss Ratings reissued a “sell (e+)” rating on shares of Geron in a research note on Wednesday, January 28th. Finally, UBS Group reaffirmed a “neutral” rating on shares of Geron in a research report on Tuesday, December 9th.

Hedge Funds Weigh In On Geron

Institutional investors and hedge funds have recently modified their holdings of the company. 55 North Private Wealth LLC acquired a new stake in Geron in the fourth quarter valued at $29,000. LCM Capital Management Inc raised its position in shares of Geron by 80.6% during the 4th quarter. LCM Capital Management Inc now owns 22,400 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 10,000 shares in the last quarter. Vistica Wealth Advisors LLC purchased a new stake in Geron during the fourth quarter worth approximately $33,000. Caitong International Asset Management Co. Ltd boosted its holdings in Geron by 3,307.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 25,148 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 24,410 shares in the last quarter. Finally, Savant Capital LLC raised its holdings in Geron by 73.8% during the second quarter. Savant Capital LLC now owns 26,074 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 11,074 shares in the last quarter. Institutional investors and hedge funds own 73.71% of the company’s stock.

Geron Stock Performance

NASDAQ GERN opened at $1.95 on Wednesday. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.96 and a quick ratio of 4.87. The company has a market cap of $1.24 billion, a P/E ratio of -16.25 and a beta of 0.62. The stock has a 50-day moving average of $1.46 and a two-hundred day moving average of $1.35. Geron has a 1-year low of $1.04 and a 1-year high of $2.42.

About Geron

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.